The Effect of Oral phenazopyrIdine on Perioperative Voiding After Mid-urethral Sling
Phase: PHASE3
Conditions: Dysfunctional Voiding, Postoperative Pain
Sponsor: University of Massachusetts, Worcester

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 1 of 10 
Revised: 6/30/16 Approved 7/7/16 
1) Title: The Effect of oral PhenazopyrIdine on Perioperative voiding  After 
mid-urethral sliNg (EPIPhANy study) 
 
2) IRB Review History* 
N/A 
3) Objectives* 
a) Primary objective: Evaluate the effect of phenazopyridine (brand name Pyridium) 
on immediate postoperative voiding function in patients undergoing midurethral 
slings  
b) Secondary objective: Evaluate percent pain reduction with and without use of oral 
Pyridium at two hours post-procedure. 
. 
4) Background* 
The midurethral sling (MUS) is a very common, highly successful 
procedure for the management of stress urinary incontinence due to 
urethral mobility, with cure rates ranging from 80 to 86%.1 A common 
complication of the MUS procedure is short-term postoperative voiding 
dysfunction. Approximately 20% (7) of patients undergoing MUS are 
unable to void in the immediate postoperative period and are discharged 
home with indwelling bladder catheter for 3-5 days.1, 2 Virtually all 
patients discharged with a catheter are able to effectively void within 5 
days of the procedure and long-term voiding dysfunction is extremely 
uncommon.  
A secondary analysis of a recent study at UMass examining the effect of 
local anesthetic on postop voiding function showed a potentially dramatic 
effect of oral phenazopyridine on reducing postoperative voiding 
dysfunction. During the study, a medication used to dye the urine blue to 
assess for ureteral injury became briefly unavailable commercially. As a 
result, we preoperatively gave all patients Pyridium because it has the side 
effect of dying the urine orange. This allowed us to evaluate the flow from 
the ureters if needed. This transition occurred in the middle of the study 
and at the conclusion, we observed that the rate of voiding dysfunction 
decreased from approximately 28% in those not receiving pyridium to 
10% in those receiving pyridium. Because the study was not designed to 
study this serendipitous finding, we propose to formally assess the validity 
of this observation.3Other than our study, there are no other publications 
that demonstrate that phenazopyridine may have an effect on 
postoperative short-term voiding dysfunction. At this time there is no 
evidence of adverse effect to denying patients phenazopyridine. Because 
of the nature of our surgical practice, many of the procedures we perform 
have the risk of ureteral injury and we made a decision to give this 
medication preoperatively to all of our patients. In the 15 years that the PI 
has practiced, we have never seen a ureteral injury in a patient undergoing 
a midurethral sling.  The documented risk of injury to the lower urinary 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 2 of 10 
Revised: 6/30/16 Approved 7/7/16 
tract during anti-incontinence surgery is approximately 2.6%, with all of 
these injuries being to the bladder or urethra and 0 ureteral injuries in 351 
cases.4 There is no place for phenazopyridine in the management or 
assessment of injuries to the bladder or urethra and many providers at 
UMass and other institutions in the US do not give phenazopyridine to 
their patients undergoing a midurethral sling. Phenazopyridine is the only 
oral medication that is available to evaluate the patency of the ureter after 
pelvic surgery.   
 
References: 
1. Nilson CG, Rezapour, M, Falconer C (2003) 7 year follow-up of the tension –
free vaginal tape (TVT) procedure. Int Urogynecol J Pelvic Floor Dysfunct 14 
(Suppl I.): S 35. 
2. Nilson CG Kuuva N, Falconer C, Rezapour M, Ulmsten U, (2001) Long term 
results of he tension-free vaginal tape (TVT) procedure for the vaginal 
treatment of female stress incontinence. Int Urogynecol J Pelvic Floor 
Dysfunct 12( Supple. 2): S5-8. 
3. Voiding function after Mid-Urethral Slings with and without local anesthetic:  
Randomized Controlled Trial. UMass IRB H-14197 
4. Tulikangas PK, Weber AM, Larive AB, Walters MD. Intraoperative 
cystoscopy in conjunction with anti-incontinence surgery. Obstet 
Gynecol. 2000 Jun;95(6 Pt 1):794-6. 
 
 
 
5) Inclusion and Exclusion Criteria* 
Inclusion criteria: 
1. Any female subjects scheduled to undergo Mid-Urethral Sling (MUS) 
through the UMass urogynecology service for incontinence. 
Exclusion criteria:  
1. Planned concurrent prolapse or other procedure besides cystoscopy 
2. Using intermittent self catheterization preoperatively 
3. Undergoing spinal anesthesia for the procedure 
4. Known allergy to phenazopyridine (AKA Pyridium)  
5. Renal insufficiency  
6. Any condition or situation that in the attending physician’s opinion would 
contra-indicate the use of phenazopyridine 
7. Subjects not competent to give consent 
8. Prisoners 
9. Non-English or non-Spanish speaking patients 
10. Age <18 
11. Pregnant patients  
12. Contraindications to the use of IV methylene blue including 
a) Patients with known hypersensitivity reactions 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 3 of 10 
Revised: 6/30/16 Approved 7/7/16 
b) Severe renal insufficiency 
c) Patients with G6PD deficiency 
 
6) Study-Wide number of Subjects* 
N/A not a multicenter study 
 
7) Study-Wide Recruitment Methods* 
 N/A not a multicenter study 
 
8) Study Timelines* 
• Participants will be enrolled in the study for approximately 6 weeks. 
• We anticipate 2 years to enroll all the subjects into the study  
• Primary analysis will be completed within 6 months after enrollment is 
completed. 
 
9) Study Endpoints* 
• Primary outcome is the rate of voiding  dysfunction between the two 
groups.  
• Secondary outcomes include: complications, perioperative pain scores,  
• Once 50% of the subjects have completed their procedures, we will 
perform an interim analysis of the rates of voiding dysfunction. If there 
is a statistically significant difference (p<0.01) at this interval analysis, 
we will terminate the study.  
 
10) 
Procedures Involved* 
Study design and randomization  
This study is a randomized controlled trial. Randomization will be 
performed using software and a block randomization scheme.  Study 
assignment will be completed using sequentially numbered sealed opaque 
envelopes. All the research procedures described other than the use or not 
of phenazopyridine will be applicable to both arms of the study. Subjects 
will have a 50% chances of getting either phenazopyridine or nothing.  
Because pyridium turns the urine orange, it is impossible to blind the 
patients and researchers to the study assignment. Because there is no 
known placebo that turns the urine orange, there is no value to using an 
actual placebo tablet. Subjects will be assigned to either receive pyridium 
or not receive pyridium preoperatively. 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 4 of 10 
Revised: 6/30/16 Approved 7/7/16 
Screening potential subjects: Investigators will screen potential subjects 
for contraindications to methylene blue. Prior obtaining the routine 
surgical consent for the potential subject’s surgical procedure, the patient’s 
medical history in the UMass Electronic Medical Record is routinely 
reviewed. The medical record will be reviewed for a diagnosis of G6PD 
and if found, the potential subject will be excluded.  
Once written consent has been obtained, subject number will be assigned 
and the appropriate randomization envelope will be opened. The study 
assignment will not be formally shared with the subject. Those assigned to 
the “pyridium” arm will have orders written for the standard 200 mg dose 
of pyridium to be given on arrival to the Surgical Admissions Care Unit 
(SACU).  Those assigned to the “NO pyridium” arm with have their 
routine preoperative orders written along with an order for “No 
preoperative pyridium”.  
Subjects will then follow the routine perioperative care for their 
procedures with the only study interventions being the gathering of PHI 
and performing postoperative pain assessments.  
PHI will be obtained at the time of the surgical consent with the purpose to 
evaluate for possible confounders affecting the postoperative bladder 
function.  
Surgical procedure: 
The Mid Urethral Sling will be performed in standard fashion based on 
manufacturer’s recommendations and instructions to minimize inter-observer 
variations. We will perform the procedure according to our usual and customary 
techniques. The subject will receive the same technique and interventions that a 
routine patient on the Urogyn service would expect to undergo.  There will be no 
changes to the technique for the purpose of the study.  
 
Bladder challenge:  
Patient will undergo voiding trial at same day surgery per our usual and 
customary protocol.  This is the same protocol the subject would undergo as a 
patient on the Urogyn service. The bladder challenge will be interpreted in our 
usual manner and the subject managed according to our routine clinical protocols.  
 
Postoperative care: 
Subjects will undergo routine postoperative care and followup. Subjects 
failing their bladder challenge will be seen in the Urogyn clinic according 
to routine clinical protocols and data councerning their void trials 
collected. Subjects will undergo routine followup evaluation 6 weeks 
postoperatively in the order to assess any potential long-term voiding 
dysfunction.  Information on any postoperative complications will be 
collected   
 
Administration of Visual analog scale: 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 5 of 10 
Revised: 6/30/16 Approved 7/7/16 
(1) Visual analog scale for assessment of pain will be administered at two time 
intervals. 
(a) VAS #1) Preoperative VAS will be done by the principal investigator or 
any of the study assistants. The VAS form will be part of subject’s packet. 
(b) VAS#2) VAS will be administered by one of the study investigators  2 to 
3 hours after the surgical procedure in the SACU.  
 
11) 
Data and Specimen Banking* 
N/A 
12) 
Data Management* 
Power Calculation: We used data from the recent “Urine and Me” study 
conducted at UMass. A 20% percent difference in subjects passing the 
bladder challenge was felt to be clinically significant.   In order to capture 
this difference a power calculation was performed via the Wilcoxon 
signed-rank test. Based on this, to detect a 20% difference with a α-error = 
0.05 and a power (1- β error) = 0.80, a minimum of 41 subjects per group 
(82 total) will need to be recruited. Assuming ~ 10% dropout rate (8), we 
will seek to recruit 90 patients. 
Data analysis: Continuous measures will be compared using the unpaired 
Student’s t test. Association between outcome measures and graph 
assignment will be adjusted according to demographic differences using 
an analysis of covariance. Standard statistical programs (SAS, SPSS) will 
be used to determine the mean differences between the voided/catheterize 
and bladder scanner volumes.   
13) 
Provisions to Monitor the Data to Ensure the Safety of Subjects* 
There is minimal risk involved with the denial of pyridium to subjects. 
Prior to the withdrawal of indigo carmine from the market in 2014, 
patients did not routinely receive pyridium preoperatively. Currently a 
minority of surgeons use pyridium in sling procedures with most using 
nothing. In the event that the ureters need to be assessed for patency, 
subjects will be given methylene blue to dye the urine. This is the 
intervention currently used to assess ureters in procedures where ureteral 
patency is assessed. Thus both groups are receiving care that is considered 
within the standard of care.  
Subjects will be monitored in a similar manner to all of our postoperative 
patients. There is a chance that pyridium may be beneficial to patients and 
that denying this medication may result in less desirable outcomes. This 
study is specifically designed to look at the issue. We plan to perform an 
interim analysis of the data once 50% of subjects have completed the 
study and if there is a clear benefit (or harm) from this medication, will 
terminate the study early and offer the medication to all patients.   
 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 6 of 10 
Revised: 6/30/16 Approved 7/7/16 
14) 
Withdrawal of Subjects* 
Subjects are free with withdraw from the study at any time. If subjects 
withdraw their participation, any data that has already been collected for 
research purposes will be destroyed or anonymized so that it can no longer 
be identified with the subject. There should not be additional data 
collection of demographic information for research purposes at the time a 
subject withdraws their consent for the study.   
  
15) 
Risks to Subjects* 
This study poses minimal risk to subjects. Subjects randomized to the 
pyridium arm will receive pyridium as it is commonly given to patients 
undergoing reconstructive procedures currently through the Urogyn 
division at UMass. Subjects denied pyridium will undergo the same 
procedures and techniques that our patients not in the study will receive.  
One risk from the study is the risk associated with denying subjects 
preoperative pyridium for their procedure. Because pyridium is used to 
dye the urine for evaluation of the ureters, in the event there is concern for 
ureteral injury, patients will be given methylene blue to dye the urine. In 
addition over the last 5 years and over 300 cases at UMass, there have 
been no cases where there has been concern for ureteral injury at the time 
of a midurethral sling placement. In patients undergoing gyn procedures 
where injury to the ureter is suspected, methylene blue is routinely given 
to evaluate for ureteral patency. Thus the patients in both arms will be 
receiving care that is considered standard for these procedures.  
Investigators will screen potential subjects for contraindications to 
methylene blue. Prior obtaining the routine surgical consent for the 
potential subject’s surgical procedure, the patient’s medical history in the 
UMass Electronic Medical Record is routinely reviewed. The medical 
record will be reviewed for a diagnosis of G6PD and if found, the 
potential subject will be excluded.  
There is a risk of unauthorized disclosure of protected health information. 
The datasheets will be kept in a locked cabinet in a locked office in the 
administrative offices of the division on Jaquith 2. The data will be 
entered into a de-identified, password protected file kept on the 
departmental computer servers.  
 
16) 
Potential Benefits to Subjects* 
Subjects who receive pyridium may have a lower rate of perioperative 
voiding dysfunction and a lower rate of perioperative catheterization.  
 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 7 of 10 
Revised: 6/30/16 Approved 7/7/16 
17) 
Vulnerable populations 
N/A 
 
18) 
Multi-Site Research* 
N/A 
19) 
Community-Based Participatory Research* 
N/A. 
 
20) 
Sharing of Results with Subjects* 
N/A. 
 
21) 
Setting  
Subjects will be identified and recruited at the urogynecology clinic located at UMass 
Memorial and the urogynecology clinic at Westborough UMass Memorial Health 
Care. The urogynecology division has two full time designated surgeons (the PI is 
one of them) and both will be part of the study. In addition one urogynecology fellow 
will work as a study assistant. All these three members will participate recruiting 
subjects and obtaining intraoperative and postoperative data.  
There will be no composition or involvement of any community advisory board, and 
this research will not be conducted outside of UMass or its affiliates.  
 
 
22) 
Resources Available 
This research will be conducted through the scheduled urogynecology 
clinic. 
Roles of the members of the study: 
• Principal investigator. Identifying potential subjects for the study, consenting of 
subjects, performing surgical procedures, participating in the data analysis, 
preparing submissions to the IRB, oversight of the conduct of the study and 
research personnel. 
• Study assistants. Identifying potential subjects for the study, consenting of 
subjects, assisting in the surgical procedures. 
• Biostatistician. The OBGYN Department has a designated biostatistician who 
will help with the data analysis. The biostatistician will not participate in the 
recruitment of study subjects.   
The PI, co-investigator and all study assistants are CITI-trained. All of 
them are also clinical members of the urogynecology division at UMass 
Memorial Medical Center Department of Obstetrics and Gynecology.  
Before initiation of the research, all study assistants will be instructed on 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 8 of 10 
Revised: 6/30/16 Approved 7/7/16 
the protocol and research procedures at the urogynecology department’s 
scheduled bimonthly research meetings. 
 
23) 
Prior Approvals 
N/A 
 
24) 
Recruitment Methods 
Subjects will be recruited through the outpatient Urogynecology clinics of 
the Urogyn faculty. Patients scheduled to undergo a midurethral slings and 
meeting criteria will be approached for participation when they present for 
their preoperative evaluation.    
 
Investigators will screen potential subjects for inclusion and exclusion 
criteria to the study including contraindications to methylene blue. Prior 
obtaining the routine surgical consent for the potential subject’s surgical 
procedure, the patient’s medical history in the UMass Electronic Medical 
Record is routinely reviewed. The medical record will be reviewed for a 
diagnosis of G6PD and if found, the potential subject will be excluded.  
 
Potential subjects will be approached by their surgeon at their preoperative 
visit.  Once eligibility has been confirmed, potential subjects will be 
offered the opportunity to participate in the study. The study will be 
reviewed in detail and ample opportunity for questions will be given.  The 
opportunity to decline participation will also be given.  For women 
agreeing to participation, informed written consent will be obtained. 
25) 
Local Number of Subjects 
90 subjects will be enrolled in the study.  
26) 
Confidentiality  
Data on participants will be stored under a participant ID number to ensure 
confidentiality.  This data will be stored initially in a locked filing cabinet 
until it can be transcribed into the redcap database which will be password 
protected on the protected redcap server. The database will be a de-
identified database. Data will be stored for seven years.  
Data security. De-identified subject data will be stored in locked filing 
cabinet in the locked office of the PI.   A study key will be maintained 
linking study numbers to subject identifiers. This dataset will be entered in 
a computer database which will be stored on a firewall protected, 
password-protected computer of the PI in a locked office.  The subject ID 
and source documents will be stored in a locked cabinet in the PI office. 
Personal identifiers will be destroyed at the earliest opportunity, no later 
than completion of the study.  

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 9 of 10 
Revised: 6/30/16 Approved 7/7/16 
 
27) 
Provisions to Protect the Privacy Interests of Subjects (HIPAA) 
Participants will be asked to sign a HIPAA authorization. The data 
collected on participants will be stored in a locked filing cabinet in the 
locked office of the primary investigator.  Only the primary investigator 
and a co-investigators will have access to it.  To further ensure 
confidentiality, all data will be stored under assigned study ID numbers 
rather than personal identifiers such as name or medical record number. 
 
28) 
Compensation for Research-Related Injury 
Because this is minimal risk, there will be no compensation for subjects 
participating in the study. In the unlikely event of research-related injury, 
no funds have been set aside and the study subject will be responsible for 
cost of care of any research related injury. 
 
29) 
Economic Burden to Subjects 
There is no economic burden to the subjects. Both groups are receiving 
care that is considered within the standard of care and all examinations, 
interventions and procedures will be occurring regardless of the subject’s 
participation in the study. The pyridium is administered as part of a global 
fee for the surgical procedure and there is no charge to the patient or her 
insurance for this medication. Because phenazopyridine is a low cost 
generic medication, its cost compared to the cost of the surgical procedure 
is negligible to the medical center. 
 
30) 
Consent Process 
The PI and study staff will  follow the UMMS Investigator Guidance for 
Informed Consent (HRP-802). Subjects who agree to participate will be 
consented per SOP at Urogynecology clinic by the attending performing 
the mid urethral sling procedure. Patients will be given ample time to 
decide and after written and verbal consent is given they will be told they 
can withdraw from study at anytime despite consenting for the study. 
Additionally, subjects will be encouraged to ask additional questions 
regarding the study and their participation. A copy of the consent will be 
provided with the principal investigator number. Subjects will be 
encouraged to call with any additional questions. 
 
Non-English Speaking Subjects 
Spanish speakers will be invited to the study. A Spanish consent translated 
from the English version will be used (attachment 8). Dr. Duenas and Dr. 
Sierra, who is a co-investigators, are native Spanish speakers, and 

INVESTIGATOR STUDY PLAN - REQUIRED 
 
 
Page 10 of 10 
Revised: 6/30/16 Approved 7/7/16 
developed the Spanish versions of the consents and summary (Attachment 
# 9). Only Dr. Duenas and Dr. Sierra will be recruiting Spanish speaking 
subjects following the same steps as above employed for English speakers.  
 
31) 
Process to Document Consent in Writing 
The PI and study staff will follow the UMMS Investigator Guidance for 
Documentation of Informed Consent (HRP-803) 
 
 
32) 
Drugs or Devices 
Phenazopyridine is a lawfully marketed drug in the United States. The 
medication is IND exempt based on the following categories: 
This medication is considered within the standard of care for the 
assessment of ureters after an urogynecologic procedure, including 
midurethral slings. The medication will be orally administered and does 
not involve a route that increases the risk associated with the use of the 
product.  
This investigation is not intended to be reported to FDA as a well-controlled study 
in support of a new indication for use nor intended to be used to support any other 
significant change in the labeling for the drug. 
 
This investigation is not intended to support a significant change in the 
advertising for the product.